Theragen Bio said Wednesday it has acquired a patent for an immunogen-predicting algorithm, a key technology for developing vaccines to prevent the spread of new infectious diseases, such as Covid-19.

The patent, called the “Computer program for predicting immunogen-predicting in treating viruses,” is an AI tech that analyzes immunity and binding based on virus dielectric data to estimate the sequencing area fit for the body.

The technology predicts the binding between the immunogenicity received from the viral-derived peptide sequence and the human leukocyte antigen (HLA) sequence that determines the tissue capability.

Theragen Bio has won a patent for an immunogen-predicting algorithm, a key technology for developing vaccines to prevent the spread of new viruses, including Covid-19. (Theragen Bio)
Theragen Bio has won a patent for an immunogen-predicting algorithm, a key technology for developing vaccines to prevent the spread of new viruses, including Covid-19. (Theragen Bio)

Based on the prediction, it designs the optimal virus antigen information, the company said.

“With the patented technology, we will be able to plan vaccine models for several virus types,” a Theragen Bio official said. “We are discussing its commercialization through the use of our genetic analysis technology and partnership with local and foreign CDMO corps.”

The patented tech applies to Covid-19, MERS, hepatitis C virus and HIV. Besides, the company has an NGS-based, virus-genomic ribonucleic acid (RNA) analysis system. With the new patent, the company has acquired an independent sequencing skill and an AI-based technology simultaneously, Theragen Bio said. 

“After developing the technology that analyzes immunogenicity for treating viruses, we decided to concentrate more on viruses that may break out in the future,” a company official told Korea Medical Review on Wednesday. 
 

Copyright © KBR Unauthorized reproduction, redistribution prohibited